General information only
The public website provides general educational and service information. It is not personal medical advice, a diagnosis, a prescription, a treatment plan, or a substitute for an assessment by a qualified healthcare professional who knows your history and circumstances.
Reading this website, submitting an enquiry, or creating an account does not by itself create a doctor-patient relationship with Nutech or any professional mentioned on the website.
A screening aid, not a diagnosis
SeroMark-1 is presented as a blood-based prostate cancer risk screening aid. A screening result estimates or groups risk within the verified intended use of the test; it does not confirm that cancer is present or absent.
No website statement should be interpreted as a promise of detection, prevention, cure, survival, or a particular clinical outcome.
Not for emergencies or urgent symptoms
Do not use this website, an enquiry form, or a screening result for emergency care. If you have severe or rapidly worsening symptoms, difficulty passing urine, significant bleeding, severe pain, collapse, or another urgent concern, contact local emergency services or an appropriate healthcare facility immediately.
A planned screening pathway must never delay urgent medical evaluation.
Suitability and patient selection
Age ranges, risk factors, or patient examples on the website are general screening information. Eligibility must follow the current approved intended use, contraindications, clinical protocol, applicable regulatory status, and the judgement of an appropriately qualified professional.
Tell the collecting or reviewing professional about relevant symptoms, diagnoses, medicines, recent procedures, infections, family history, and previous prostate investigations where requested. These factors may affect suitability or interpretation.
Sample collection and preparation
Nutech's current approved workflow states that the blood sample is collected while the patient is fasting. Final instructions from the approved collection provider or doctor take priority because preparation may change with the verified protocol, another test ordered at the same visit, or an individual medical circumstance.
Collection, identification, transport, storage, analysis, and reporting should occur through the authorized and quality-controlled pathway. Do not send a sample independently unless the current service specifically permits it.
Results and test limitations
Every screening test has limitations. A lower-risk result cannot rule out cancer, and a borderline or elevated result does not mean that cancer has been diagnosed. False-negative, false-positive, indeterminate, delayed, invalid, or non-reportable outcomes may occur within the limitations of the method and sample.
Risk bands, thresholds, performance statements, and report wording must be interpreted only within the current validated population, intended use, analytical method, quality controls, and approved documentation. They may be revised as evidence or requirements develop.
Clinical interpretation and follow-up
A qualified doctor should interpret the report alongside symptoms, age, family history, examination findings, previous results, medicines, and other relevant information. Follow-up may involve observation, repeat testing, PSA testing, examination, imaging, referral, biopsy, or another step chosen by the responsible doctor.
Do not start, stop, or change a medicine or treatment, postpone an appointment, or decline a recommended investigation solely because of website content or a SeroMark-1 result.
Does not replace established care
SeroMark-1 should not be treated as a replacement for professional medical advice or for PSA testing, clinical examination, imaging, biopsy, pathology, surveillance, or treatment where any of those are appropriate. Its role must remain within the current verified clinical pathway.
Regulatory status and availability
In-vitro diagnostic medical devices in India are governed through the applicable medical-device framework and are classified according to risk. Product, facility, laboratory, import, manufacture, sale, distribution, labelling, performance, and post-market obligations may differ according to the device and activity.
Nothing on this website should be treated as evidence that SeroMark-1 has received a particular authorization, classification, endorsement, reimbursement decision, or clinical-guideline recommendation. Current status, intended use, approved labelling, availability, and permitted claims must be verified from final Nutech documentation and the appropriate authority before use.
Timelines, locations, and access
Nutech's current approved material states a four-day laboratory turnaround from sample receipt to report. This is not a guarantee for every appointment. Delays can arise from collection, transport, sample quality, repeat quality checks, system availability, holidays, or doctor review.
Confirm the facility, appointment, fees, preparation, report route, and follow-up arrangements before travelling or making a healthcare decision.
Independent doctors and providers
Doctors, hospitals, laboratories, collection providers, and other organizations may exercise independent professional judgement and have their own duties, terms, privacy practices, accreditation, and complaint routes. A link or reference does not by itself establish endorsement or responsibility for independent services.
Research and investor content
Descriptions of research priorities, scientific concepts, opportunities, platform plans, or future studies are not proof of clinical performance or authorization. Investor and partnership content is not medical evidence and should not guide patient care.
Questions and corrections
Ask your treating doctor about personal medical decisions. General website or product-information questions, suspected errors, and accessibility requests may be sent to nutechkpk@gmail.com. Do not send identifiable medical records by ordinary email unless Nutech provides an approved secure route.